Skip to main content

Table 3 Demographic and clinical characteristics of adult onset Still’s disease in elderly cases [4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41]

From: Adult onset Still’s disease in the elderly: a case-based literature review

Clinical Characteristics Total (N, %)a Patients with MASb (N, row %) Patients without MAS (N, row %) p-value*
Patient count 42 (100%) 10 (23.81%) 32 (76.19%)  
AGE (YEAR), (MEDIAN, IQR) 75, 7 74.5, 8 75, 6 0.49
Female 34 (80.95%) 10 (23.81%) 24 (57.14%) 0.16
Fever 42 (100%) 10 (23.81%) 32 76.19%) 1.00
Rash 34 (80.95%) 10 (23.81%) 24 (57.14%) 0.16
Pruritic rash 9 (21.43%) 4 (9.52%) 5 (11.90%) 0.23
Arthralgia/Myalgia 38 (90.48%) 7 (16.67%) 31 (73.81%) 0.04
Serositis 7 (16.67%) 1 (2.38%) 6 (14.29%) 0.49
Hepatosplenomegaly 14 (33.33%) 3 (7.14%) 11 26.19%) 0.06
Sore throat 22 (52.38%) 6 (14.29%) 16 (38.10%) 0.31
Leukocytosis, (Median, IQR) 13,700, 8800 9000, 5895 16,000, 9470 < 0.01
Hyperferritinemia, (Median ± IQR) 5336, 15,447 41,932, 70,250 2684, 7821 < 0.01
Transaminitis 28 (66.67%) 7 (16.67%) 21 (50.0%) 1.00
Delayed Diagnosis (>  1 month) 38 (90.48%) 9 (21.43%) 29 (69.05%) < 0.01
Corticosteroids 39 (92.36%) 9 (21.43%) 30 (71.43%) 0.28
NSAIDsc 14 (33.33%) 1 (2.38%) 13 (30.95%) 0.04
Conventional DMARDsd 17 (40.48%) 5 (11.90%) 12 (28.57%) 0.15
Biologic DMARDs 8 (19.05%) 3 (7.14%) 5 (11.90%) 0.09
Miscellaneous Treatment 8 (19.05%) 3 (7.14%) 5 (11.90%) 0.09
  1. a All percentages are based on the overall patients in total (42 patients)
  2. b MAS Macrophage activation syndrome
  3. c NSAIDs Nonsteroidal anti-inflammatory drugs
  4. c DMARDs Disease-modifying anti-rheumatic drugs
  5. * Wilcoxon rank sum test, Chi-square test, or Fisher’s exact test was applied where it is appropriate. Statistical tests used two-sided hypothesis testing